Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:CRNX NASDAQ:PTGX NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.36+0.2%$33.90$22.24▼$46.00$2.16B0.541.16 million shs890,007 shsCRNXCrinetics Pharmaceuticals$83.73+0.1%$49.37$25.83▼$84.00$8.83B0.238.54 million shs2.34 million shsPTGXProtagonist Therapeutics$136.11+0.5%$116.79$50.49▼$143.29$8.75B1.79823,448 shs298,402 shsSYRESpyre Therapeutics$102.13+2.1%$85.42$14.51▼$105.09$8.98B3.021.36 million shs811,705 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%-8.20%+0.44%+43.60%-10.36%CRNXCrinetics Pharmaceuticals0.00%-0.16%+139.30%+118.45%+170.27%PTGXProtagonist Therapeutics0.00%-3.41%+10.99%+36.11%+151.17%SYRESpyre Therapeutics0.00%+1.90%+15.18%+46.59%+473.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.36+0.2%$33.90$22.24▼$46.00$2.16B0.541.16 million shs890,007 shsCRNXCrinetics Pharmaceuticals$83.73+0.1%$49.37$25.83▼$84.00$8.83B0.238.54 million shs2.34 million shsPTGXProtagonist Therapeutics$136.11+0.5%$116.79$50.49▼$143.29$8.75B1.79823,448 shs298,402 shsSYRESpyre Therapeutics$102.13+2.1%$85.42$14.51▼$105.09$8.98B3.021.36 million shs811,705 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%-8.20%+0.44%+43.60%-10.36%CRNXCrinetics Pharmaceuticals0.00%-0.16%+139.30%+118.45%+170.27%PTGXProtagonist Therapeutics0.00%-3.41%+10.99%+36.11%+151.17%SYRESpyre Therapeutics0.00%+1.90%+15.18%+46.59%+473.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$42.7817.65% UpsideCRNXCrinetics Pharmaceuticals 2.29Hold$78.27-6.52% DownsidePTGXProtagonist Therapeutics 2.94Moderate Buy$123.00-9.63% DownsideSYRESpyre Therapeutics 2.92Moderate Buy$101.42-0.70% DownsideCurrent Analyst Ratings BreakdownLatest AGIO, PTGX, CRNX, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$54.00 ➝ $52.007/17/2026CRNXCrinetics Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026PTGXProtagonist Therapeutics Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.007/17/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/14/2026PTGXProtagonist Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$119.00 ➝ $151.007/13/2026SYRESpyre Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$84.00 ➝ $120.007/8/2026CRNXCrinetics Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/8/2026PTGXProtagonist Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/7/2026AGIOAgios Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$28.00 ➝ $32.007/7/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $41.007/7/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $46.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$66.05M32.74N/AN/A$20.46 per share1.78CRNXCrinetics Pharmaceuticals$7.70M1,146.56N/AN/A$9.71 per share8.62PTGXProtagonist Therapeutics$46.02M190.21N/AN/A$9.83 per share13.85SYRESpyre Therapeutics$890K10,091.36N/AN/A$7.21 per share14.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)CRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest AGIO, PTGX, CRNX, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026PTGXProtagonist Therapeutics$2.11N/AN/AN/A$199.81 millionN/A8/4/2026Q2 2026CRNXCrinetics Pharmaceuticals-$1.23N/AN/AN/A$14.84 millionN/A8/4/2026Q2 2026SYRESpyre Therapeutics-$0.71N/AN/AN/AN/AN/A7/30/2026Q2 2026AGIOAgios Pharmaceuticals-$1.6588N/AN/AN/A$26.07 millionN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59CRNXCrinetics PharmaceuticalsN/A18.6018.56PTGXProtagonist TherapeuticsN/A17.7617.76SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ACRNXCrinetics Pharmaceuticals98.51%PTGXProtagonist Therapeutics98.63%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%CRNXCrinetics Pharmaceuticals3.80%PTGXProtagonist Therapeutics5.19%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableSYRESpyre Therapeutics7387.94 million74.14 millionOptionableAGIO, PTGX, CRNX, and SYRE HeadlinesRecent News About These CompaniesSpyre Therapeutics, Inc. $SYRE is Affinity Asset Advisors LLC's 6th Largest PositionJuly 25 at 3:12 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading 5.7% Higher - Should You Buy?July 17, 2026 | marketbeat.comWhy Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 10.35%July 14, 2026 | aaii.comASpyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year High After Analyst UpgradeJuly 14, 2026 | marketbeat.comEmerald Advisers LLC Sells 22,744 Shares of Spyre Therapeutics, Inc. $SYREJuly 14, 2026 | marketbeat.comSpyre Therapeutics Stock Dividends | NASDAQ:SYRE | BenzingaJuly 13, 2026 | benzinga.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, Mizuho Analyst SaysJuly 13, 2026 | marketbeat.comCandriam S.C.A. Buys 184,748 Shares of Spyre Therapeutics, Inc. $SYREJuly 12, 2026 | marketbeat.comJefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)July 6, 2026 | theglobeandmail.comInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $658,050.00 in StockJuly 3, 2026 | insidertrades.comSpyre Therapeutics Announces Grants of Inducement AwardsJuly 2, 2026 | globenewswire.comSpyre Therapeutics, Inc. $SYRE Stock Holdings Decreased by Pictet Asset Management Holding SAJuly 2, 2026 | marketbeat.comSpyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting DataJune 30, 2026 | seekingalpha.comIs SYRE Stock a Buy Now or a Wait-and-See Biotech Story TodayJune 29, 2026 | zacks.comSpyre Therapeutics Stock Outlook Hinges on 2026 Study CatalystsJune 29, 2026 | zacks.comSYRE and Spyre Ride New IBD Trends in Biotech Drug DesignJune 29, 2026 | zacks.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $1,306,950.00 in StockJune 27, 2026 | insidertrades.comSpyre Therapeutics: A Platform Where The Combination Strategy Is The Real AssetJune 26, 2026 | seekingalpha.comBiotech ETF Index Surges 10% After RebalanceJune 25, 2026 | etftrends.comESpyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)June 24, 2026 | finance.yahoo.comMichael Thomas Henderson Sells 20,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 24, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026AGIO, PTGX, CRNX, and SYRE Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$36.36 +0.08 (+0.22%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$36.33 -0.03 (-0.10%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Crinetics Pharmaceuticals NASDAQ:CRNX$83.73 +0.08 (+0.10%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$83.73 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Protagonist Therapeutics NASDAQ:PTGX$136.11 +0.68 (+0.50%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$136.15 +0.04 (+0.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Spyre Therapeutics NASDAQ:SYRE$102.13 +2.14 (+2.14%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$103.00 +0.87 (+0.85%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
